MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel , July 11, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or “the Company”) announced Larry Jasinski, Chief Executive Officer, will present virtually at the Emerging Growth Conference at 10:15 am EDT on Wednesday, July 12, 2023.
For investors who are interested in participating, please use the link below to register and receive any conference updates: https://goto.webcasts.com/starthere.jsp?ei=1603282&tp_key=1cd1dcc46a&sti=rwlk
For attendees who are unable to join the event live, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, An archived link to the presentation will be available on the Company’s website after the event.
About ReWalk Robotics Ltd.:
ReWalk Robotics Ltd. is a medical device company that designs, develops, and commercializes innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions. ReWalk’s mission is to fundamentally change the quality of life for these individuals through the creation and development of market leading technologies. Founded in 2001, ReWalk has operations in the U.S., Israel, and Germany. For more information on the ReWalk systems, please visit rewalk.com.
ReWalk® and ReStore® are registered trademarks of ReWalk Robotics Ltd. in the United States and other jurisdictions.
| ReWalk Investor Contact: Michael Lawless Chief Financial Officer ReWalk Robotics Ltd. E: This email address is being protected from spambots. You need JavaScript enabled to view it. | ReWalk Media Relations: John Tomlin E: This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$0.67 |
| Daily Change: | -0.0027 -0.40 |
| Daily Volume: | 1,029,050 |
| Market Cap: | US$7.120M |
May 19, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
